A5015139202- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Cancer therapeutics and mechanisms
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Menopause: Health Impacts and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- SARS-CoV-2 and COVID-19 Research
- Cytokine Signaling Pathways and Interactions
- Lymphoma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- COVID-19 and healthcare impacts
- Breast Cancer Treatment Studies
- Cancer-related Molecular Pathways
- Estrogen and related hormone effects
- COVID-19 Impact on Reproduction
Università Cattolica del Sacro Cuore
2021-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2024-2025
Agostino Gemelli University Polyclinic
2021-2025
Abstract Precision oncology has transformed non-small cell lung cancer (NSCLC) treatment by tailoring therapies to the genomic profile of disease, significantly improving clinical outcomes. However, acquired resistance molecularly targeted remains a major challenge. This report details 69-year-old woman with KRAS G12C-mutant metastatic NSCLC who developed sotorasib, G12C inhibitor. Initially responding standard dose 960 mg, patient required reduction 480 mg due liver toxicity. After 20...
Background: As COVID-19 has become an epidemic, we conducted open-label study aimed to identify immunogenicity and reactogenicity of boosters the BNT162b2 vaccine in a real-world cohort long-survivor metastatic lung cancer patients (LS-mLC pts). Methods Analysis: According timing booster dose (BD) SARS-CoV-2 infection (Cov-I) during anticancer treatment (ACT), between October 2021 February 2022, prospectively enrolled 166 into five parallel cohorts. The primary endpoints were seroprevalence...
ABSTRACT Background It is reported that treatment with anaplastic lymphoma kinase (ALK) tyrosine inhibitors (TKIs) induces hypogonadism both in male patients ALK‐positive cancer and murine models. Methods In this study, three groups, including an experimental group of ALK‐positive, advanced non–small cell lung (ANSCLC) who were receiving alectinib (cohort A), a control female ANSCLC B), ALK‐negative C), prospectively underwent full hormone assessment for androgen deficiency at 8 weeks after...
Aims: This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer response first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Methods: Patients received pembrolizumab alone (n = 213) associated chemotherapy 81). Results: A mutation the gene was detected 27% patients. In patients on alone, median progression-free survival KRAS-mutated cases longer than wild-type (11.3 vs 4.4 months; p 0.019), whereas overall...
Introduction Gastric cancer (GC) is the fourth leading cause of cancer-related death worldwide with limited therapeutic options. The aim this study was to analyze value adding surgery first-line treatment in patients oligometastatic GC (OGC). Methods This retrospective included OGC who underwent induction chemotherapy followed by both primary tumor and synchronous metastasis between April 2012 2022. Endpoints were overall survival (OS) relapse-free (RFS) analyzed Kaplan–Meier method....
Fusion events involving NRG-1, a member pan-HER pathway, have been highlighted as potential therapeutic target; however, little is known about epidemiological distribution and prognostic value of NRG alterations in large real-world datasets. Data from 592 patients with newly diagnosed ANSCLC undergone to CGP DNA RNA-based NGS (TSO500) Jan 2020 Oct 2023 were retrospectively collected the context FPG500 program (interventional monocentric prospective study, NCT06020625). analysis reported...
e20129 Background: The addition of immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy (CT-IO) has changed the first-line (1L) treatment landscape extensive-stage small-cell lung cancer (ES-SCLC). Although ICIs improve survival, they can trigger related adverse events (irAEs). Notably, a correlation between irAEs and improved survival (OS) been observed in several solid tumours including NSCLC. impact multiorgan ES-SCLC treated with 1L CT-IO remains less clear. Methods: We...
PURPOSE The clinical and research FPG500 program (ClinicalTrials.gov identifier: NCT06020625 ) is currently ongoing at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS to tailor matched targeted therapies (MTTs) according biomarkers predictive of response identified by comprehensive genome profiling (CGP). MATERIALS AND METHODS non–small cell lung cancer (NSCLC) cohort results from are outlined. CGP was performed TruSight Oncology 500 High Throughput (TSO500HT) assay or...
IO ± chemotherapy (CT) is first-line therapy for mNSCLC without actionable mutations. We aimed to identify a genomic signature potentially predicting resistance using NGS. Pts with who received or CT/IO were eligible. NGS was performed by TSO500HT® assay (DNA [522 genes], RNA [55 Tumor Mutational Burden, Microsatellite Instability) Oncomine Focus Assay® (DNA, 35 genes) plus Archer's FusionPlex Lung Panel® (RNA, 17 genes), according quality/quantity cellularity. A least absolute shrinkage and...